The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.

Eli Lilly stock gains as the FDA removes tirzepatide drugs from the drug shortage list following a thorough reevaluation.

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 471.82% and ...

US doctors write billions of prescriptions each year. During 2024, though, one type of drug stood out—“wonder drugs” known as ...

Hope was diagnosed with very high cholesterol and fatty liver disease, and says her weight was ruining her life ...

Up to a third of the weight lost while taking weight loss jabs such as Wegovy and Mounjaro includes muscle and bone mass.

The FDA has declared the end of the two-year shortages of Eli Lilly's Mounjaro and Zepbound — used to treat diabetes and weight loss, respectively — and has reaffirmed its decision to halt the ...

Tirzepatide includes blockbuster injected GLP-1 medications Mounjaro (for diabetes) and Zepbound (for weight loss).

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...